{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T19:35:31Z","timestamp":1781811331992,"version":"3.54.5"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013317","name":"Shanxi Provincial Key Research and Development Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Aprepitant, fosaprepitant, and netupitant are three common neurokinin-1 receptor antagonists (NK-1RAs) used to prevent chemotherapy-induced nausea and vomiting, following highly or moderately emetogenic chemotherapy. Understanding their different adverse event (AE) profiles may help clinicians make appropriate treatment decisions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All data collected from the FDA Adverse Event Reporting System (FAERS) database from the first quarter of 2004 to the fourth quarter of 2023 underwent disproportionality analysis to detect, evaluate, and compare AE signals of the three NK-1RAs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 3,904, 1,123, and 243 AE reports related to aprepitant, fosaprepitant, and netupitant, respectively, were extracted from the FAERS database. Of these, more than 50% of respondents were female, and most of them were aged 45\u201365\u00a0years. General disorders and administration-site conditions, and gastrointestinal disorders were the most frequent signals in the system organ class of the three NK-1RA drugs. In addition, aprepitant was strongly associated with joint deposit (ROR = 26.27) and fosaprepitant was closely related to seizure-like phenomena (ROR = 26.90); two preferred terms (PTs) were not mentioned in the manual. Statistically, netupitant was likely to induce death (N = 63, ROR = 8.78, 95% CI: 6.75\u201311.42). Additionally, neutropenic colitis, colitis, and stomatitis were unique to netupitant. Furthermore, the AE profiles of the three NK-1RA drugs were different by gender.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The AE profiles for aprepitant, fosaprepitant, and netupitant were different. In addition to paying attention to common AEs, clinicians need to pay attention to new emerging AEs, such as joint deposit, seizure-like phenomena, neutropenic colitis, colitis, and stomatitis, regarding the three NK-1RA drugs. Furthermore, the AE compositions of the three NK-1RA drugs were different in different genders, and clinicians should take these factors into account when selecting NK-1RAs for CINV treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1413709","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T04:25:52Z","timestamp":1722399952000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety assessment of neurokinin-1 receptor antagonist: real-world adverse event analysis from the FAERS database"],"prefix":"10.3389","volume":"15","author":[{"given":"Chuanli","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhe","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiushan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1634\/theoncologist.2014-0229","article-title":"Aprepitant and fosaprepitant: A 10-year review of efficacy and safety","volume":"20","author":"Aapro","year":"2015","journal-title":"Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/annonc\/mdu101","article-title":"A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy","volume":"25","author":"Aapro","year":"2014","journal-title":"Ann. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.6004\/jnccn.2012.0049","article-title":"Corticosteroids in the treatment of chemotherapy-induced nausea and vomiting","volume":"10","author":"Barbour","year":"2012","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"B4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2217\/fon-2018-0662","article-title":"Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: a retrospective study","volume":"15","author":"Boccia","year":"2019","journal-title":"Future Oncol. Lond. Engl."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1517\/17425255.2010.513970","article-title":"Pharmacokinetic evaluation of fosaprepitant dimeglumine","volume":"6","author":"Colon-Gonzalez","year":"2010","journal-title":"Expert Opin. Drug Metabolism Toxicol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/annonc\/mdm104","article-title":"Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy","volume":"18","author":"Durand","year":"2007","journal-title":"Ann. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s40265-016-0627-7","article-title":"Fosaprepitant dimeglumine: a review in the prevention of nausea and vomiting associated with chemotherapy","volume":"76","author":"Garnock-Jones","year":"2016","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"100278","DOI":"10.1016\/j.ctarc.2020.100278","article-title":"Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends","volume":"26","author":"Gupta","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1021\/jm990617v","article-title":"Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs","volume":"43","author":"Hale","year":"2000","journal-title":"J. Med. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/annonc\/mdu110","article-title":"Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study","volume":"25","author":"Hesketh","year":"2014","journal-title":"Ann. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1182\/blood-2012-07-446054","article-title":"Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12","volume":"121","author":"Janelsins","year":"2013","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1080\/17512433.2019.1621162","article-title":"Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults","volume":"12","author":"Karthaus","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4103\/jpp.JPP_182_16","article-title":"Ifosfamide-induced encephalopathy precipitated by aprepitant: a rarely manifested side effect of drug interaction","volume":"8","author":"Kataria","year":"2017","journal-title":"J. Pharmacol. Pharmacother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s40265-015-0512-9","article-title":"Netupitant\/palonosetron: a review in the prevention of chemotherapy-induced nausea and vomiting","volume":"75","author":"Keating","year":"2015","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.3390\/ijms23052583","article-title":"Substance P, a promising therapeutic target in musculoskeletal disorders","volume":"23","author":"Ko","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1586\/17512433.1.1.27","article-title":"Aprepitant for the prevention of nausea and vomiting associated with chemotherapy and postoperative recovery","volume":"1","author":"Larusso","year":"2008","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1017889","DOI":"10.3389\/fphar.2022.1017889","article-title":"Ocular adverse events associated with anti-VEGF therapy: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS)","volume":"13","author":"Ma","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.4103\/0019-509X.123580","article-title":"A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis","volume":"50","author":"Maru","year":"2013","journal-title":"Indian J. Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1177\/1078155220971794","article-title":"Incidence of ifosfamide induced encephalopathy in patients receiving concomitant fosaprepitant","volume":"27","author":"Modi","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s13555-019-0305-2","article-title":"NK-1 receptor antagonists and pruritus: review of current literature","volume":"9","author":"Pojawa-Go\u0142\u0105b","year":"2019","journal-title":"Dermatology Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1002\/cncr.11433","article-title":"Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America","volume":"97","author":"Poli-Bigelli","year":"2003","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ctrv.2015.09.005","article-title":"Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: rolapitant and NEPA (Netupitant\/Palonosetron)","volume":"41","author":"Rojas","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1007\/s12325-018-0707-z","article-title":"Safety of polysorbate 80 in the oncology setting","volume":"35","author":"Schwartzberg","year":"2018","journal-title":"Adv. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1159\/000368184","article-title":"Two cases of fatal encephalopathy related to ifosfamide: an adverse role of aprepitant?","volume":"7","author":"S\u00e9journ\u00e9","year":"2014","journal-title":"Case Rep. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s40265-021-01558-2","article-title":"Netupitant\/palonosetron: a review in chemotherapy-induced nausea and vomiting","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1177\/1078155214527143","article-title":"An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center","volume":"21","author":"Szabatura","year":"2015","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3892\/mco.2016.769","article-title":"Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: a retrospective comparison","volume":"4","author":"Tsuda","year":"2016","journal-title":"Mol. Clin. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-022-04439-x","article-title":"Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review","volume":"90","author":"Vazirian","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12325-018-0862-2","article-title":"Efficacy, tolerability and pharmacokinetic impact of aprepitant in sarcoma patients receiving ifosfamide and doxorubicin chemotherapy: a randomized controlled trial","volume":"36","author":"Xiong","year":"2019","journal-title":"Adv. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"701","DOI":"10.17219\/acem\/157061","article-title":"The clinical research study for fosaprepitant to prevent chemotherapy-induced nausea and vomiting: a review","volume":"32","author":"Xue","year":"2023","journal-title":"Adv. Clin. Exp. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1413709\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T04:25:55Z","timestamp":1722399955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1413709\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":31,"alternative-id":["10.3389\/fphar.2024.1413709"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1413709","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"article-number":"1413709"}}